MIIST: A New Modality for Controlling Innate Immunomodulatory Signaling
The human body is protected from insult and injury by important mucosal and dermal barriers. Damage to these barriers initiates an innate immune response that can result in hyperimmune cascades and lead to systemic inflammation. Synedgen’s Multivalent Innate Immune Surface Target (MIIST) platform modulates mucosal signaling after damage to manage the cycle of inflammation, infection, and injury.
Our chemical approach has produced a scientifically validated, diversified drug pipeline able to protect the human body’s natural barriers from radiation, chemical, and traumatic damage. MIIST therapeutics:
Our Discovery Process
Synedgen’s glycopolymer discovery process selects targets that have been conserved through millions of years of evolution. We optimize glycopolymer chemistry to design target-specific therapeutics that are selective for disease physiology.